Abogen Biosciences is a fully integrated clinical-stage new powerhouse in the evolving field of RNA therapeutics. Driven by the mission to revolutionize the future of health and life, we are committed to pioneering mRNA medicines through innovation, integration and insight.
Founded in 2019, we have been rapidly rising to prominence in biotechnology powered by our proprietary clinically validated mRNA-LNP platform that combines advanced AI technologies, automation and scalable manufacturing. With deep expertise in mRNA modifications and delivery, we are pushing the boundaries of immuno-oncology, autoimmune disease therapies and infectious disease vaccines.
At the crossroads of science, technology and healthcare, we aspire to deliver transformative medicines through mRNA innovations, turning the impossible into reality.
-
AccountableWe dedicate ourselves to patients. With the mission to deliver transformative medicines through scientific innovations, we encourage everyone to be a true leader with integrity, urgency, and a strong commitment to timelines and results.
-
BoldWe relentlessly focus on finding meaningful breakthroughs and transformative solutions to otherwise untreatable diseases. We strive to challenge norms, seek truth with facts and data, and innovate fearlessly for an ultimate answer through trial and error.
-
Open-mindedThere is no permanent authority in scientific research. By advocating openness and diversity, we create an inclusive workplace where talents are respected, different ideas are heard, and curiosity is cherished. We learn from one another and bring out the best in each other.
Dr. Bo Ying has over 15 years of experience in the pharmaceutical industry and is widely recognized as a renowned scientist. He previously served as a senior scientist at Dicerna and Moderna where he led a wide range of projects on oligonucleotide and mRNA-based product development and large-scale production. He has extensive experience in product development in disease areas such as oncology, infectious diseases and rare diseases.
Dr. Ying obtained a bachelor's degree in biology and a master's degree in neurobiology from Fudan University, and a Ph.D. degree in pharmaceutical sciences from Northeastern University in the United States.
Ms. Wenjie Song has over 20 years of experience in clinical development and leadership in the pharmaceutical industry. Ms. Song served in various senior leadership roles in several industry-leading biotechnology companies and multinational corporations, including AstraZeneca, Johnson & Johnson and Novartis, primarily responsible for clinical development of oncology-related drug products.
Ms. Song obtained her bachelor's degree in clinical medicine and her master's degree in Obstetrics and Gynecology from Zhengzhou University.
Dr. Peng Gao, head of mRNA Development, has over 13 years of experience in biopharmaceutical research and development, with 30 published papers in vaccine development, antibody engineering and enzyme engineering as well as four approved patents. He previously served as the head of research at Ruiyang (Suzhou) Biotech Co., Ltd., and as a senior scientist at the University of Texas Health Science Center.
Dr. Gao obtained his bachelor's degree in genetics and master's degree in molecular genetics from Nankai University, and a Ph.D. degree in molecular biology from the University of Texas at Austin in the United States.
Ms. Song has approximately 20 years of experience in investment banking, corporate finance, healthcare investment management as well as corporate senior management positions. Prior to joining Abogen, Ms. Song served as the CFO for a leading oncology biotechnology company and various senior positions in a number of financial institutions including BAML, UBS and CLSA.
Ms. Song obtained her bachelor's degree from the University of Chicago and her master's degree in medical sciences from the University of Hong Kong.
Dr. McFadyen previously held senior positions at Moderna Therapeutics. He received his Ph.D. degree from the School of Science, Loughborough University.
Dr. Zhang Zhiyi has extensive experience in pharmaceutical formulation development and innovative drug delivery technologies. Prior to joining Abogen, Dr. Zhang held senior positions at Hospira (acquired by Pfizer in 2015), Shire (acquired by Takeda in 2019), Daiichi Sankyo and Arcturus Therapeutics.
Dr. Zhang obtained his Ph.D. degree in synthetic chemistry from Kyushu University in Japan.
Dr. Ma Xinpeng has over 13 years of experience in pharmaceutical research, drug development, and academic leadership. Dr. Ma previously took senior roles in BIND Therapeutics, Moderna and Harebell Pharmaceutical Technologies.
Dr. Ma obtained Ph.D. degree in chemical engineering from the University of Wyoming in the United States.
Dr. Xiaotao Wang has over 15 years of experience in pharmaceutical research and development. Prior to joining Abogen, Dr. Wang held senior positions at Bristol Myers Squibb, Johnson & Johnson, GSK, and AstraZeneca.
Dr. Wang obtained his Ph.D. degree in Biochemistry/Molecular Biology from The University of Hong Kong.
-
The human body has incredible potentials, and it just needs the right message of what proteins to synthesize to fight against diseases. As we further advance our technology platform, we believe mRNA will completely transform the way how medicines are made and how diseases are treated.—— Bo Ying, Ph D, Founder, Chairman and CEO
Bo Ying, Ph.D.Founder, Chairman and CEODr. Bo Ying has dedicated over a decade of his career to the technology research into nucleic acid -based therapeutics and the development of transformative drugs. He founded Abogen, a biotechnology company with a mission of curing otherwise untreatable diseases through mRNA science and technology.
As the founder, Dr Ying also has served as Chairman of the board and CEO of Abogen. Under his leadership, the company has established its own proprietary mRNA platform and delivery technology that allowed the development of the therapeutics and vaccines for infectious diseases, cancer, and rare diseases. Most recently, Abogen’s mRNA platform capabilities have come together to allow the authorized use and approval of first China made mRNA vaccine against the COVID-19 pandemic.
Prior to founding Abogen, Dr Ying had held several roles at numerous leading biopharmaceutical and biotechnologies companies in the US, mainly responsible for leading drug formulation, process development, technology transfer and manufacturing. Across his career, he takes pride in a broad array of innovative drug developing experiences in siRNA, mRNA-based therapies for tumor immunotherapy、cancer vaccines and gene-editing drug product candidates.
Dr. Ying received his bachelor’s degree in life sciences from Fudan University, Shanghai, and Ph.D. in pharmaceutical sciences from Northeastern University. He is credited as the inventor of a dozen issued patents and patent applications, and his work appears in journals such as Cell and Lancet.
Over the years, Dr. Ying has held several positions in influential organizations. From 2018 to 2019, he served as the president of the Chinese-American BioMedical Association (CABA) in Boston, where he made contributions to the advancement of science and technological innovation with great potential to improve human health.